🚀 VC round data is live in beta, check it out!
Radiopharm Theranostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Radiopharm Theranostics and similar public comparables like Boundless Bio, Jiangsu Wuzhong Pharmaceutical, Celularity, Mendus and more.
Radiopharm Theranostics Overview
About Radiopharm Theranostics
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Founded
2021
HQ
Employees
14
Website
Sectors
Financials (LTM)
EV
$14M
Radiopharm Theranostics Financials
Radiopharm Theranostics reported last 12-month revenue of $1M.
In the same LTM period, Radiopharm Theranostics generated ($497K) in gross profit and had net loss of ($39M).
Revenue (LTM)
Radiopharm Theranostics P&L
In the most recent fiscal year, Radiopharm Theranostics reported revenue of $3M and EBITDA of ($27M).
Radiopharm Theranostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | ($497K) | XXX | $28K | XXX | XXX | XXX |
| Gross Margin | (44%) | XXX | 1% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($27M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1050%) | XXX | XXX | XXX |
| EBIT Margin | (3761%) | XXX | (953%) | XXX | XXX | XXX |
| Net Profit | ($39M) | XXX | ($25M) | XXX | XXX | XXX |
| Net Margin | (3504%) | XXX | (965%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Radiopharm Theranostics Stock Performance
Radiopharm Theranostics has current market cap of $35M, and enterprise value of $14M.
Market Cap Evolution
Radiopharm Theranostics' stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14M | $35M | 2.3% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRadiopharm Theranostics Valuation Multiples
Radiopharm Theranostics trades at 12.3x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Radiopharm Theranostics Financial Valuation Multiples
As of April 18, 2026, Radiopharm Theranostics has market cap of $35M and EV of $14M.
Equity research analysts estimate Radiopharm Theranostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Radiopharm Theranostics has a P/E ratio of (0.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35M | XXX | $35M | XXX | XXX | XXX |
| EV (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV/Revenue | 12.3x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.6x) | XXX | XXX | XXX |
| EV/Gross Profit | (27.9x) | XXX | 493.0x | XXX | XXX | XXX |
| P/E | (0.9x) | XXX | (1.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Radiopharm Theranostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Radiopharm Theranostics Margins & Growth Rates
Radiopharm Theranostics' revenue in the last 12 month grew by 34%.
Radiopharm Theranostics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.8M for the same period.
Radiopharm Theranostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | (69%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1050%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 868% | XXX | 455% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2504% | XXX | 863% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 954% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Radiopharm Theranostics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Radiopharm Theranostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Boundless Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Wuzhong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Celularity | XXX | XXX | XXX | XXX | XXX | XXX |
| Mendus | XXX | XXX | XXX | XXX | XXX | XXX |
| Generation Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Radiopharm Theranostics M&A Activity
Radiopharm Theranostics acquired XXX companies to date.
Last acquisition by Radiopharm Theranostics was on XXXXXXXX, XXXXX. Radiopharm Theranostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Radiopharm Theranostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRadiopharm Theranostics Investment Activity
Radiopharm Theranostics invested in XXX companies to date.
Radiopharm Theranostics made its latest investment on XXXXXXXX, XXXXX. Radiopharm Theranostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Radiopharm Theranostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Radiopharm Theranostics
| When was Radiopharm Theranostics founded? | Radiopharm Theranostics was founded in 2021. |
| Where is Radiopharm Theranostics headquartered? | Radiopharm Theranostics is headquartered in Australia. |
| How many employees does Radiopharm Theranostics have? | As of today, Radiopharm Theranostics has over 14 employees. |
| Who is the CEO of Radiopharm Theranostics? | Radiopharm Theranostics' CEO is Riccardo Canevari. |
| Is Radiopharm Theranostics publicly listed? | Yes, Radiopharm Theranostics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Radiopharm Theranostics? | Radiopharm Theranostics trades under RAD ticker. |
| When did Radiopharm Theranostics go public? | Radiopharm Theranostics went public in 2021. |
| Who are competitors of Radiopharm Theranostics? | Radiopharm Theranostics main competitors are Boundless Bio, Jiangsu Wuzhong Pharmaceutical, Celularity, Mendus. |
| What is the current market cap of Radiopharm Theranostics? | Radiopharm Theranostics' current market cap is $35M. |
| What is the current revenue of Radiopharm Theranostics? | Radiopharm Theranostics' last 12 months revenue is $1M. |
| What is the current revenue growth of Radiopharm Theranostics? | Radiopharm Theranostics revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Radiopharm Theranostics? | Current revenue multiple of Radiopharm Theranostics is 12.3x. |
| Is Radiopharm Theranostics profitable? | No, Radiopharm Theranostics is not profitable. |
| What is the current net income of Radiopharm Theranostics? | Radiopharm Theranostics' last 12 months net income is ($39M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.